Certara Services Archives

Case Study

Using Real Word Evidence to Enhance Drug Development

Real-world evidence (RWE) has emerged as an increasingly important tool in the drug development process,1…

CertaraApril 5, 2023

Conference

RAPS Convergence 2025

– – Booth

CertaraMarch 20, 2023

Conference

ACCP Annual Meeting

– – Booth

CertaraJuly 15, 2022

Case Study

Leveraging Clinical Data from One Rare Disease to Support Drug Approval for Another

Atypical hemolytic uremic syndrome (aHUS) is an ultra-rare genetic disease that causes abnormal blood clot…

CertaraJune 1, 2022

Blog

Choosing an eCTD Submissions Vendor: Your Complete Checklist

September 3, 2025 Selecting the right electronic submission vendor for regulatory submissions to health authorities…

CertaraJanuary 28, 2022

Blog

A Bird’s Eye View on Rare Diseases: Key Drug Development Considerations for Thyroid Eye Disease

New therapeutics discovery and development for ocular diseases have been traditionally associated with a low…

CertaraDecember 15, 2021

Case Study

Dose Optimization Using Population PK for an Orphan Drug

RAPALIMUS® Tablets (sirolimus) is Nobelpharma’s orphan drug developed from an oral medication that is sold…

CertaraNovember 17, 2021

Case Study

Defining path-to-market strategy through a data-driven and scientific approach

How Certara supported a gene therapy manufacturer by using a selection of gateway and value…

CertaraOctober 28, 2021

White Paper

Using Real-world Evidence to Advance Market Access for New Therapeutics

CertaraSeptember 29, 2021

On-Demand Webinar

The Scary Future of Rare Disease Management

In a world of rising healthcare costs, the greatest nightmare for payers is reimbursing drug…

CertaraSeptember 23, 2021

Certara Services

Using Real Word Evidence to Enhance Drug Development

RAPS Convergence 2025

ACCP Annual Meeting

Leveraging Clinical Data from One Rare Disease to Support Drug Approval for Another

Choosing an eCTD Submissions Vendor: Your Complete Checklist

A Bird’s Eye View on Rare Diseases: Key Drug Development Considerations for Thyroid Eye Disease

Dose Optimization Using Population PK for an Orphan Drug

Defining path-to-market strategy through a data-driven and scientific approach

Using Real-world Evidence to Advance Market Access for New Therapeutics

The Scary Future of Rare Disease Management

Newsletter sign up

Quick links

Solutions

Contact